Product Description
Organon is developing Etoricoxib as a treatment for Osteoarthritis. (Sourced from: https://clinicaltrials.gov/study/NCT00242489)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Mexico
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Acute Pain|Low Back Pain
Phase 2: Pain, Postoperative
Phase 1: Osteoarthritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SIL-30952-III-23(1) | P3 |
Completed |
Acute Pain|Low Back Pain |
2024-10-04 |
|
| LT-04-20 | P2 |
Completed |
Acute Pain|Pain, Postoperative |
2022-08-18 |
|
| SIL-30138-III-21(1) | P3 |
Completed |
Acute Pain|Low Back Pain |
2022-03-15 |
95% |
| CTR20230210 | P1 |
Not yet recruiting |
Osteoarthritis |
None |